BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mensing S, Eckert D, Sharma S, Polepally AR, Khatri A, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. Br J Clin Pharmacol 2017;83:527-39. [PMID: 27662429 DOI: 10.1111/bcp.13138] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Mensing S, Eckert D, Sharma S, Polepally AR, Khatri A, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. Br J Clin Pharmacol 2017;83:527-39. [PMID: 27662429 DOI: 10.1111/bcp.13138] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
2 Hecht M, Veigure R, Couchman L, S Barker CI, Standing JF, Takkis K, Evard H, Johnston A, Herodes K, Leito I, Kipper K. Utilization of data below the analytical limit of quantitation in pharmacokinetic analysis and modeling: promoting interdisciplinary debate. Bioanalysis 2018;10:1229-48. [PMID: 30033744 DOI: 10.4155/bio-2018-0078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
3 Zha J, Ding B, Wang H, Zhao W, Yu C, Alves K, Mobashery N, Luo Y, Menon RM. Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients. Eur J Drug Metab Pharmacokinet 2019;44:43-52. [PMID: 29909549 DOI: 10.1007/s13318-018-0492-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Badri PS, Shuster DL, Dutta S, Menon RM. Clinical Pharmacokinetics of Ombitasvir. Clin Pharmacokinet 2017;56:1103-13. [PMID: 28229375 DOI: 10.1007/s40262-017-0518-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
5 Polepally AR, Wang H, Marroum PJ, Minocha M, Hosmane B, Khatri A, Mensing S, Podsadecki TJ, Cohen DE, Awni WM, Menon RM. Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection. AAPS J 2017;19:1523-35. [PMID: 28685397 DOI: 10.1208/s12248-017-0115-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Gopalakrishnan S, Mensing S, Menon RM, Zha J. Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies. Clin Pharmacokinet 2018;57:1407-19. [PMID: 29516428 DOI: 10.1007/s40262-018-0640-y] [Reference Citation Analysis]
7 King JR, Zha J, Khatri A, Dutta S, Menon RM. Clinical Pharmacokinetics of Dasabuvir. Clin Pharmacokinet 2017;56:1115-24. [PMID: 28258380 DOI: 10.1007/s40262-017-0519-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
8 Hasan M, Parvez MSA, Azim KF, Imran MAS, Raihan T, Gulshan A, Muhit S, Akhand RN, Ahmed SSU, Uddin MB. Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach. Biomed Pharmacother 2021;140:111742. [PMID: 34052565 DOI: 10.1016/j.biopha.2021.111742] [Cited by in F6Publishing: 2] [Reference Citation Analysis]